©The Author(s) 2016.
World J Gastroenterol. Jul 28, 2016; 22(28): 6393-6401
Published online Jul 28, 2016. doi: 10.3748/wjg.v22.i28.6393
Published online Jul 28, 2016. doi: 10.3748/wjg.v22.i28.6393
Table 1 Drugs for hepatitis C virus treatment
| Mechanism of action | Drug | Genotype |
| Protease inhibitor | Telaprevir | 1 |
| Boceprevir | 1 | |
| Simeprevir | 1 | |
| Paritaprevir | 1, 4 | |
| Grazoprevir | 1, 4 | |
| Asunaprevir1 | 1 | |
| ABT-4501 | 1 | |
| Faldaprevir1 | 1 | |
| NS5A inhibitors | Daclatasvir | 1, 3 |
| Ombitasvir | 1, 4 | |
| Ledipasvir | 1, 4, 5, 6 | |
| Elbasvir | 1, 4 | |
| Velpatasvir1 | 4 | |
| NS5B inhibitors | ||
| Nucleotide-analogue | Sofosbuvir | 1, 2, 3, 4, 5, 6 |
| Non-nucleoside analogue | Dasabuvir | 1 |
| Beclabuvir1 | 1 |
- Citation: Bastos JCS, Padilla MA, Caserta LC, Miotto N, Vigani AG, Arns CW. Hepatitis C virus: Promising discoveries and new treatments. World J Gastroenterol 2016; 22(28): 6393-6401
- URL: https://www.wjgnet.com/1007-9327/full/v22/i28/6393.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i28.6393